Mar 19, 2019 4:30pm EDT DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
Mar 18, 2019 1:56pm EDT DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
Mar 12, 2019 1:00pm EDT DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
Feb 14, 2019 7:00am EST DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
Jan 22, 2019 7:45am EST DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
Jan 09, 2019 5:00pm EST DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
Jan 03, 2019 8:09am EST DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
Nov 12, 2018 4:45pm EST DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
Nov 06, 2018 5:00pm EST DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
